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Tissue regeneration requires inflammatory and repar-
atory activity of macrophages. Macrophages detect
and eliminate the damaged tissue and subsequently
promote regeneration. This dichotomy requires the
switch of effector functions of macrophages coordi-
nated with other cell types inside the injured tissue.
The gene regulatory events supporting the sensory
and effector functions of macrophages involved in
tissue repair are not well understood. Here we show
that the lipid activated transcription factor, PPARg,
is required for proper skeletal muscle regeneration,
acting in repair macrophages. PPARg controls the
expression of the transforming growth factor-b
(TGF-b) family member, GDF3, which in turn regu-
lates the restoration of skeletal muscle integrity by
promoting muscle progenitor cell fusion. This work
establishes PPARg as a required metabolic sensor
and transcriptional regulator of repair macrophages.
Moreover, this work also establishes GDF3 as a
secreted extrinsic effector protein acting on myo-
blasts and serving as an exclusively macrophage-
derived regeneration factor in tissue repair.
INTRODUCTION
Tissues suffer damage during an organism’s lifetime. In order
to maintain the body’s integrity and homeostasis, it is critically1038 Immunity 45, 1038–1051, November 15, 2016 ª 2016 Elsevier Iimportant to achieve complete regeneration. In many cases, a
straightforward paradigm can be applied whereby organ injury
induces expansion and differentiation of a quiescent population
of tissue-specific stem-cell-like progenitors. Impaired injury-
related immune response has been shown to greatly influence
regeneration in liver, central nervous system, or skeletal muscle
(Chazaud, 2014; Duffield et al., 2005; Laflamme andMurry, 2011;
Rapalino et al., 1998). Immune cells and in particular macro-
phages sense the injury, remove damaged tissues, then initiate
restoration of tissue integrity via promoting repair mechanisms.
During this latter phase the immune response regulates the
reengagement of tissue progenitor cell populations to support
cell growth and differentiation. Our knowledge is fragmented
on how macrophages employ sensory and regulatory mecha-
nisms and use effector functions to serve their reparatory roles.
We sought to identify such integrated regulatory mechanisms
that equip a macrophage with the capacity to contribute to a
timely progression of repair.
We found that the fatty acid regulated transcription factor,
peroxisome proliferator-activated receptor gamma (PPARg)
(Tontonoz et al., 1998), was required in repair macrophages dur-
ing skeletal muscle regeneration. Mice with a deletion of PPARg
in their myeloid lineages showed a pronounced delay in regen-
eration. PPARg regulated the expression of a secreted factor,
GDF3, in repair macrophages. GDF3 deficiency impaired mus-
cle regeneration and recombinant GDF3 enhanced repair in vivo
and the fusion of primary myogenic precursor cells (MPCs) in
in vitro cultures. Our data reveal a PPARg-GDF3 pathway with
sensory, gene regulatory, and effector components in which
PPARg in repair macrophages responds to signals and support
the timely promotion of tissue repair during skeletal muscle
regeneration.nc.
RESULTS
PPARg Is Expressed in Macrophages of the Cardiotoxin
Induced Skeletal Muscle Injury Model
Skeletal muscle possesses robust regenerative capacity; there-
fore, it provides us with an excellent model system to study
regeneration. The best characterized experimental model of
skeletal muscle injury is the toxin-induced injury and regenera-
tion. We triggered skeletal muscle damage in the tibialis ante-
rior (TA) muscle of mice by intramuscular injection of the snake
venom, Cardiotoxin (CTX), to induce a homogenous and
synchronous muscle damage that is repaired with the active
contribution of infiltrating immune cells. We isolated macro-
phage populations from injured muscle and interrogated their
gene-expression profiles by microarray analysis. When the
expression profiles of inflammatory Ly6C+ and repair Ly6C
macrophages derived from injured muscle at day 2 CTX injury
were compared, gene ontology (GO) annotation categories
belonging to lipid and carbohydrate metabolism dominated the
biological processes that were the most robustly upregulated
in the Ly6C (repair) macrophages (Figure S1A). When analyzing
the expression data, we found that a master regulator of meta-
bolism, Pparg, was highly expressed in these macrophages.
Using publicly available gene-expression data within the Immu-
nological Genome Project, we compared the expression of
Pparg in muscle infiltrative macrophages to that of their direct
precursors, Ly6C+ monocytes (Varga et al., 2013), and various
other myeloid cells (Figure S1B). We found that Pparg in muscle
macrophages was highly expressed, and that only two in vivo
macrophage subtypes, alveolar macrophages and splenic
red pulp macrophages expressed Pparg higher. In contrast to
Pparg, Ppara was not expressed in muscle infiltrative macro-
phages, while the expression of Ppard showed a declining
expression in the course of regeneration (Figure S1C).
On the basis of these findings, we hypothesized that macro-
phage PPARg is a metabolic sensor and regulator of skeletal
muscle regeneration. To test this hypothesis, we used the
Ppargfl/fl Lyz2-cremouse strain, which is deficient in PPARg spe-
cifically in myeloid lineages (Clausen et al., 1999). When CD45+
cells, which comprise all infiltrating hematopoietic cells, or
sortedmacrophages, were isolated from injured skeletal muscle,
the expression of Ppargwas detected in these cells by RT-qPCR
(Figures S1D and S1E) in wild-type (WT) animals. Furthermore,
the expression ofPpargwas greatly diminished in corresponding
CD45+ cells and macrophages isolated from Ppargfl/fl Lyz2-cre
animals, validating the suitability of this genetic model for these
experiments.
Macrophage PPARg Regulates Skeletal Muscle
Regeneration
WT and Ppargfl/fl Lyz2-cre animals were injected with CTX to
induce TA muscle injury and then regeneration was analyzed
by a combination of morphometric and flow cytometry analysis.
We found Ppargfl/fl Lyz2-cre animals showed a pronounced
delay in muscle regeneration (Figures 1A–1D and S2A). First,
the cross-sectional area (CSA) of the regenerating muscle fibers
was significantly smaller in thePpargfl/fl Lyz2-cre than inWTmice
at day 8 and day 21 following CTX injury (Figures 1C and S2A).
Second, there were a significantly higher number of phagocyticand/or necrotic fibers present at day 8 post CTX in Ppargfl/fl
Lyz2-cre mice (Figures 1A and 1B), indicating either a delayed
clearance of dying myofibers or an altered dynamics of muscle
fiber death in Ppargfl/fl Lyz2-cre animals. Third, increased inflam-
matory infiltration persisted in small regions in the regenerative
areas in Ppargfl/fl Lyz2-cre muscles at day 8 (Figure 1A), which
were resolved by day 21 (Figure S2B). Next, we wanted to
ascertain whether PPARg deficiency in the hematopoietic
compartment was the major contributor to the observed pheno-
type. To prove this, we used a second genetic model, in which
bone marrow from the epiblastic conditional ablation of Pparg
(Ppargfl/, Sox2-cre+) (Nadra et al., 2010) or WT animals were
used to reconstitute the hematopoietic compartment in irradi-
ated WT animals (bone marrow transplanted or BMT animals).
TA muscles of recipient BMT animals were injected with CTX
12 weeks after BMT and histological analysis of muscle regener-
ation was carried out 22 days post injury. When compared
with animals that received WT bone marrow (WT BMT), mice
that received bone marrow deficient in PPARg (Ppargfl/,
Sox2-cre+ BMT) exhibited a profound deficit in regeneration
(Figures 1E and 1F). Further underlying the importance of PPARg
in muscle regeneration, full body Ppargfl/ Sox2-cre+ animals
displayed impairment in their skeletal muscle regeneration
(Figure S2C).
PPARg Deficiency Does Not Alter Macrophage
Infiltration or Differentiation in Injured Muscle
Several possible reasons could explain whymacrophage PPARg
deficiency leads to such impairment in muscle regeneration.
One underlying reason behind our observations could be a
decreased macrophage infiltration in Ppargfl/fl Lyz2-cre animals.
To monitor the cellular dynamics of immune infiltration in CTX
injured muscle, we treated WT and Ppargfl/fl Lyz2-cre animals
with CTX, then isolated and analyzed immune cells from injured
muscles on days 1, 2, or 4, using CD45+ magnetic bead selec-
tion. We found no major difference between the numbers and
types (Ly6Cmid F4/80 neutrophils, Ly6C+ F4/80low, and Ly6C
F4/80high macrophages) of infiltrating immune cells in WT vs.
Ppargfl/fl Lyz2-cre animals (Figure S3), with the exception of mi-
nor alterations in the ratio of neutrophils at day 1 and in the total
number of CD45+ cells at day 6.
Next, wewanted to explorewhichmacrophage functionsmight
be relevant tomuscle regenerationand regulatedbyPPARgactiv-
ity. To test the possible contribution of impaired phagocytosis,
we used bone-marrow-derived macrophages (BMDMs) isolated
from WT or Ppargfl/fl Lyz2-cre animals, and from bone marrow
transplanted WT BMT or Ppargfl/fl, Sox2-cre+ BMT animals (Fig-
ures S4A for experimental setup and S4B for data). We set up a
phagocytosis assay, in which fluorescently labeled necrotic
C2C12 myoblasts were co-incubated with BMDMs labeled with
a different fluorescent dye. Ppargfl/fl Lyz2-cre BMDMs showed
no significant increase in the number of phagocyting BMDMs
or in the amount of phagocytosed substrate as compared with
WT BMDMs (Figure S4B). Similar results were obtained using
BMDMs derived from WT BMT or Ppargfl/, Sox2-cre+ BMT ani-
mals, except that Ppargfl/, Sox2-cre+ BMT BMDMs were
able to phagocytose a greater load. Our results indicated that
an inadequate phagocytic clearance was unlikely to be respon-
sible for the observed delay.Immunity 45, 1038–1051, November 15, 2016 1039
Figure 1. Impaired Regeneration of Skeletal Muscle in PPARg-Deficient Animals
(A) Representative images of HE stained skeletal muscle from WT and Ppargfl/fl Lyz2-cre animals prior (day 0) or post CTX induced injury (day 8) are shown.
Asterisk labels phagocytic and/or necrotic fibers and arrow points to foci of inflammatory infiltrations. IHC detection of desmin (red), F4/80 (green), and nuclei
(blue) at day 8 post CTX injury is also shown. Scale bars in the upper left represent 50 mm.
(B) The ratio of phagocytic and/or necrotic fibers relative to all regenerative fibers at day 8 of regeneration in WT and Ppargfl/fl Lyz2-cremuscle sections is shown.
(C) Fiber size repartition of regenerating muscle in WT or Ppargfl/fl Lyz2-cre animals at day 8 and day 21 post CTX injury.
(D) Average fiber cross section area (CSA) of regenerating muscle at indicated timepoints post CTX injury in WT and Ppargfl/fl Lyz2-cre animals.
(E) n = (numbers of individual muscles, derived from WT or Ppargfl/fl Lyz2-cre mice): 4 and 4 for day 0 samples, 5 and 6 for day 8 samples, 5 and 5 for day 21
samples and 5 and 5 for day 63 samples, respectively. Representative images of HE stained skeletal muscle 22 days after CTX injury from bone marrow
transplanted (BMT) animals that received either WT or Ppargfl/ Sox2-cre bone marrow.
(F) Muscle fiber CSA of BMT animals 22 days post CTX injury. n = 8 muscles for both genotypes. In all bar graphs, mean values ± SEM are shown. For Pparg
expression in macrophages and CD45+ cells and for additional histological analysis, see Figures S1 and S2. For the FACS analyses of infiltrating cells, see
Figure S3.
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Figure 2. PPARg-Regulated Macrophage Functions and Genes
(A) Effect of BMDM derived conditioned media on the proliferation of primary myoblasts (± SEM). n= 4 or 3 for WT or Ppargfl/fl Lyz2-cre BMDM supernatant.
(B) Effect of BMDM derived conditioned media on the differentiation of primary myotubes (± SEM). For the complete analysis, see Figures S4C and S4D. n = 6 for
both genotypes.
(C–E) Transcriptional analysis of the Ly6C+ and Ly6Cmacrophage populations derived fromWT andPpargfl/fl Lyz2-cre animals. For schematics of comparisons,
see Figure S4F.
(C) Heatmap representation of genes that show differential (p = 0.05, min. 1.5X FC) expression in the four sorted WT vs. Ppargfl/fl Lyz2-cremacrophages in day 1
Ly6C+, D2 Ly6C+ and D2 Ly6C, and D4 Ly6C cells (labeled as D1 Ly6C+ etc.). In each heatmap, the differentially expressed genes are highlighted within a red
square and the expression pattern of these genes in the other macrophage subtypes is also shown for reference. Blue and red arrows label genes that are
(legend continued on next page)
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Macrophage PPARg Regulates Myoblast Differentiation
in a Paracrine Manner In Vitro
These results led us to test whether macrophage PPARg activity
confers a yet unidentified muscle differentiation-promoting
phenotype to macrophages, which could explain the observed
delayed muscle regeneration in animals deficient in PPARg in
macrophages. To test this hypothesis, we used in vitro muscle
precursor cell proliferation or differentiation assays that utilize
primary myoblasts isolated from WT mice (Figures 2A and 2B).
In the first assay, we cultured primary myoblasts with condi-
tioned medium derived from non-treated, interferon-g (IFN-g),
or interleukin-4 (IL-4)-treatedWT and Ppargfl/fl Lyz2-creBMDMs,
in conditions favoring cell proliferation and measured the prolif-
eration index by detecting Ki67+ cells by immunofluorescence
(IF). As expected, conditioned medium derived from IFN-g-
treated WT BMDMs increased myoblast proliferation (Mounier
et al., 2013). Conditioned medium from non-treated Ppargfl/fl
Lyz2-cre BMDMs phenocopied the proliferation enhancing ef-
fect of inflammatory WT BMDMs on myoblasts (Figure 2A).
These results indicated that PPARg in macrophages modulated
an unknown signaling system that could influence myoblast
proliferation in a paracrine manner. Next, we tested the effect
of BMDM-derived conditioned media on the differentiation of
myoblasts by counting the number of cell nuclei within freshly
formed desmin-positive myotubes cultured in differentiation
medium (Figure 2B and Figure S4C). As expected, we observed
a large increase in differentiation when myoblasts were grown
in conditioned medium derived from IL-4-treated WT BMDMs.
Importantly, this increased differentiation was abrogated
when conditioned medium from IL-4-treated Ppargfl/fl Lyz2-cre
BMDMs was added to differentiating myoblasts. This effect
was seen in several independently isolated primary myoblast
cell lines that were used for the experiments (Figure S4C).
BMDM supernatant derived from IFN-g-treated cells, on the
other hand, did not alter myoblast differentiation (Figure S4D).
Our results raised the possibility that similar PPARg-dependent
paracrine signaling events took place in situ during regeneration,
where muscle infiltrative macrophages and MPCs might interact
to achieve a synchronized and timely regeneration.
PPARg Regulates Cell-Type-Specific Genes in Muscle
Infiltrating Macrophages
Next, we set out to identify PPARg-dependent regulatory cir-
cuits that connect macrophages to myotube differentiation in a
paracrine manner. Because PPARg is a transcription factor, we
presumed that a relevant change in the gene expression in mus-
cle macrophages must shed light on the regulatory circuit that is
abrogated in Ppargfl/fl Lyz2-cre macrophages. We isolated pop-
ulations of macrophages from regenerating muscle fromWT and
Ppargfl/fl Lyz2-cre animals and analyzed their gene-expression
profiles by microarrays (Figures 2C–2E and S4E and S4F). We
selected inflammatory Ly6C+ macrophages at day 1 and 2,
and repair Ly6C macrophages at day 2 and 4 post CTX injurydownregulated or upregulated in WT vs. Ppargfl/fl Lyz2-cre cells, respectively. The
For RT-qPCR validation of mRNA expression, see Figure S5.
(D) Top 5 up and downregulated genes in the four sorted macrophage population
differences (FC). Gdf3 and Apold1, the genes that are down- or upregulated in P
(E) Venn-diagrams show the overlap of the number of genes that are down- or up
1042 Immunity 45, 1038–1051, November 15, 2016and compared their gene expression by two-way ANOVA tests
(Table S1). We created heatmaps for all four examined macro-
phage subsets (Figure 2C). These heatmaps show all genes
that were differentially expressed in one relevant subset and
also show the expression pattern of these genes in all the other
macrophage subsets. The top five genes that were most differ-
entially regulated in WT vs. Ppargfl/fl Lyz2-cre cells are shown
in Figure 2D. The number of genes that were concordantly
regulated in a PPARg-mediated manner in more than one
macrophage subtypes is shown in Figure 2E. We hypothesized
those genes could be under regulation by PPARg that were
expressed differently in more than one subtype of muscle
macrophages. Accordingly, we combined the lists of upregu-
lated genes reported by the ANOVA analysis of WT vs. Ppargfl/fl
Lyz2-cre comparisons. Although many genes were differentially
regulated in a single type of muscle macrophages, only five
genes (Saa3, Hebp1, Plxnd1, Apold1, Tsg101) were upregulated
in all four investigated subtypes of PPARg-deficient muscle
macrophages (Figure 2E and Table S1). Next, we analyzed the
gene sets that were downregulated in Ppargfl/fl Lyz2-cre macro-
phages. There was only one gene, namely growth differentiation
factor 3 (Gdf3), that was consistently downregulated in all four
investigated macrophage populations (Figures 2D and 2E).
Thus, we identified several putative PPARg target genes that
showed consistent PPARg dependency in more than one
muscle macrophage subsets. To ascertain the PPARg-depen-
dent regulation of some representative genes, we measured
the mRNA expression of Gdf3, Apold1, Hebp1, and Plxnd1 by
RT-qPCR in macrophage subsets sorted from injured muscle
(Figure S5A). This analysis confirmed the results derived from
the microarray experiments. The expression pattern of a short
panel of previously described PPARg-dependent (M2) alter-
native genes (Odegaard et al., 2007) indicated that the repair
macrophages in CTX injured muscles were not canonical M2
macrophages, and that PPARg exerted little, if any, influence
on their expression (Figure S5B). Along the same line, while a
total body deficiency in STAT6, the master regulator of IL4
signaling, caused increased presence of phagocytic and/or
necrotic fibers at day 8 (Figure S5C), it did not affect the CSA
of new myofibers (Figure S5D).
The genes we identified as PPARg-dependent in muscle mac-
rophages did not belong to the group of canonical PPARg-regu-
lated genes described in various myeloid cells in earlier studies
(such as Plin2, Cd36, Angptl4, or Fabp4) (Szanto et al., 2010;
Welch et al., 2003). One possible reason for this discrepancy
could be that most in vitro studies apply synthetic or natural li-
gands of PPARg to study the transcriptional activity of the recep-
tor upon ligand activation. Therefore, we wanted to see whether
synthetic PPARg ligand activation of infiltrating macrophages
gave rise to transcriptional changes that are more reminiscent
of the list of previously identified PPARg target genes. For
this reason, we treated WT animals with rosiglitazone (RSG) via
gavage and analyzed the ligand dependent gene expressionblue and red arrows point to the direction of increasing fold change difference.
s in Ppargfl/fl Lyz2-cremacrophages. Table lists gene symbols and fold change
pargfl/fl Lyz2-cre in all four subtypes, are highlighted in color.
regulated in Ppargfl/fl Lyz2-cremacrophages in the four analyzed populations.
changes in macrophages (Figures S4F and S5E, and Table S1).
We found that many more genes were regulated by RSG treat-
ment in Ly6C+ than in Ly6C cells. Again, the genes that showed
differential expression upon RSG treatment in Ly6C+ cells did not
contain established PPARg-regulated genes, nor the six differ-
ently regulated genes that appeared to be under PPARg regula-
tion in all macrophage subsets. Although RSG treatment caused
the differential regulation of fewer genes in Ly6C cells, the most
robustly upregulated gene was Angptl4, one of the best-charac-
terized PPARg target genes. This suggests that not only Ly6C
macrophages at day 2 expressed PPARg, but that the receptor
was also sensitive to the activating effect of an exogenous ligand
in Ly6C cells. It is important to note thatGdf3, the gene that was
found to be consistently downregulated in Ppargfl/fl Lyz2-cre
macrophage subsets, was also regulated by RSG treatment
(only) in Ly6C macrophages. Next, we took the list of 43 genes
that showed ligand dependent upregulation in Ly6C macro-
phages upon RSG treatment and created a heatmap representa-
tion to see how these genes were regulated in the absence of
RSG treatment (Fig S5E). Even without RSG treatment, most of
the otherwise RSG dependent genes showed a characteristic in-
duction as Ly6C+ macrophages differentiated into Ly6C cells
and an even further induction by day 4. This observation raised
the intriguing possibility that the underlying reason behind the
limited number of PPARg ligand regulated genes in Ly6Cmac-
rophages was that most of these genes were already induced
during muscle regeneration, even in the absence of exogenous
synthetic ligand treatment. Related to this hypothesis, we de-
tected a dynamic in situ regulation of eicosanoid synthesis dur-
ing regeneration. While inflammatory eicosanoids (e.g., PGE2
and PGF2a) were detectable in the early inflammatory stages of
injury, they were later replaced by lipid mediators produced by
murine 12/15-lipoxygenase (Alox15) that have been implicated
in ligand activation of PPARg such as 12-HETE and 15-HETE
(Figure S5F) (Huang et al., 1999).
GDF3 Is a Macrophage-Derived PPARg-Dependent
Member of the TGF-ß Family
To focus on putative PPARg regulated genes whose activity
could promote muscle regeneration, we interrogated the list
of differently expressed genes for genes that (1) were PPARg-
dependent in more than one macrophage subset, (2) coded a
secreted factor and (3) whose activity might be linked to muscle
differentiation. Of note, one gene, Gdf3 (Levine and Brivanlou,
2006; Levine et al., 2009; Shen et al., 2009), fit all these criteria.
Gdf3 was statistically significantly downregulated in Ppargfl/fl
Lyz2-cre cells in all four investigated macrophage subsets (Fig-
ures 2D and 2E, Table S1). GDF3 belongs to the TGF-b family,
whose members are secreted factors acting in a paracrine
manner. Finally, several members of the TGF-b family are known
regulators of muscle regeneration, including GDF8 (also known
as Myostatin) (McPherron et al., 1997). Therefore, we selected
Gdf3 as the most likely PPARg-dependent gene that contributes
to muscle regeneration for further analysis.
PPARg Occupies a Complex Set of Active Enhancers
around the Gdf3 Locus
Next, we wanted to characterize the genomic events that are
responsible for the regulation of Gdf3 by PPARg. We electedto use BMDMs, a readily available in vitro model system that al-
lowed us to employ high-throughput genomic and epigenomic
methods to interrogate the regulatory mechanism exerted by
PPARg on the Gdf3 locus. We established that WT and Ppargfl/fl
Lyz2-cre BMDMs provided a platform with good correlation
to study the PPARg-dependent regulation of Gdf3, as PPARg
deficiency in BMDMs abrogated the expression of both the ca-
nonical PPARg target gene Angptl4 and that of Gdf3 (Figure 3A).
Then, we compiled epigenomic and genomic data to identify the
relevant enhancers that were active and possibly under PPARg
regulation in BMDMs (Figure 3B).We includedCTCF as a binding
factor of insulator regions and RAD21, as a component of the
cohesin complex to determine the boundaries of potential chro-
matin loops or topological domains, PU.1 as a key lineage deter-
mining factor in macrophages, RXR (the obligate heterodimeric
partner of PPARg), and PPARg chromatin immunoprecipitation
(ChIP)-seq data derived from thioglycolate elicited peritoneal
macrophages and adipocytes. We combined these data with
active epigenetic marks from H3K4me3 ChIP-seq experiments
and GRO-seq data from BMDMs. Based on the common
CTCF and RAD21 binding sites (Daniel et al., 2014; Merkenschl-
ager and Odom, 2013), the transcription unit of Gdf3 appeared
to be approximately between 50 Kb to +50 Kb. Our definition
of putative, active enhancers included (1) binding of PU.1, (2)
presence of detectable enhancer transcript (GRO-seq signal),
and (3) RXR or PPARg binding. This approach was validated
by applying the same criteria to the Angptl4 locus, in which we
readily identified its PPARg-dependent enhancer (Figure S6A).
On the basis of these criteria, we nominated 14 putative active
enhancers at a distance from +38 Kb to 47 Kb relative
to the transcription start site of Gdf3 (Figures 3B and S6B).
As we show in Figure 3C, binding of PPARg and RXR could
be readily detected on five of these selected enhancers
(at +7.3 Kb, 21 Kb, 25 Kb, 44 Kb, and 47 Kb) if we
comparedWT to Ppargfl/fl Lyz2-creBMDMs. These data strongly
suggested that Gdf3 was regulated by one or several of these
PPARg:RXR binding sites.
GDF3 Is a Regulator of Myoblast Proliferation,
Differentiation and Muscle Regeneration
Next, we analyzed the GDF3 protein expression in whole muscle
lysates of CTX injured WT mice, which provided a snapshot of
GDF3 protein level during regeneration. The protein expression
followed the induction seen at the mRNA level in macrophages
and showed a pronounced induction, which peaked at day 4
(Figure 4A), at the time when inflammation subsides and regen-
erative processes start to dominate within the injured muscle.
Importantly, the induction of GDF3 expression was detectable
in the CD45+ (hematopoietic) compartment and was diminished
at both mRNA and protein amount in Ppargfl/fl Lyz2-cre animals
(Figures 4B–4D). Next, we further investigated GDF3 expression
in alternative models of muscle injuries. We found that, similarly
to CTX injury, GDF3 protein expression was induced during
glycerol-mediated injury and regeneration in WT but diminished
in PPARg macrophage-deficient animals (Figure 4E). Further-
more, not only themRNA expression ofGdf3, but the entire panel
of genes that showed strong PPARg dependency in the CTX
model, was regulated concordantly in the two models of injury
(Figure 4F). GDF3 protein expression was also induced inmuscleImmunity 45, 1038–1051, November 15, 2016 1043
Figure 3. Gdf3 Is a PPARg Target Gene in BMDMs
(A) mRNA expression (± SD) of Angptl4, a canonical PPARg target gene, Pparg,Gdf3, and Apobec1, a nearby, not regulated gene, are shown in BMDMs (n = 4 for
WT and n = 5 for Ppargfl/fl Lyz2-cre).
(B) Identification of possible enhancers around the Gdf3 locus. The selection criteria for enhancers possibly involved in Gdf3 regulation are described in the text
and in Figures S6A and S6B. Putative enhancers are labeled by vertical lines. Blue verticals highlight enhancers without PPARg ChIP enrichment, red verticals
label enhancers where enrichment in PPARg binding in WT BMDMs was detected by PPARg ChIP.
(C) ChIP on the putative enhancer regions reveal PPARg binding at +7.3 Kb, 21 Kb, 25 Kb, 44 Kb, and 47 Kb enhancers around the Gdf3 locus.
Representative graphs showing PPARg, RXR, or IgG ChIPs carried out on two samples are shown. Angptl4 enhancer and Gdf3 +16 Kb enhancer are shown as
positive and negative controls, respectively.
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Figure 4. GDF3 mRNA and Protein Expres-
sion in Regenerating Muscles
ES and B stand for embryonic stem cells and
blank, respectively.
(A) GDF3 protein expression in whole-muscle
lysates of regenerating muscles from WT mice at
different timepoints (D, day).
(B) GDF3 mRNA expression in CD45+ and CD45
cells isolated at day 4 post CTX injury fromWT and
Ppargfl/fl Lyz2-cre mice (M, mouse).
(C) Decreased protein expression of GDF3 in
CD45+ cells isolated from Ppargfl/fl Lyz2-cre
animals.
(D) mRNA expression (± SD) of Gdf3 in CD45+ and
CD45 cells isolated from injured muscles at days
1, 2, and 4 post CTX in WT and Ppargfl/fl Lyz2-cre
animals. n = 4 for each day, cell type, and geno-
type.
(E) GDF3 protein expression detected in muscles
lysates generated from glycerol mediated injuries
(M, mouse).
(F) Concordant mRNA expression pattern (± SD)
of PPARg-dependent genes in CTX and Glycerol
mediated injuries. n = 3 for both treatments.
(G) GDF3 protein expression detected in muscle
lysates generated from crush or freeze injuries
(R and L stand for right and left leg, respectively).
(H) Specificity of the anti-GDF3 antibody is
demonstrated in day 4 CTX injured WT and
Gdf3/ muscle samples.samples exposed to crush- and freeze-injuries, which are toxin-
free methods (Figure 4G). Due to recent publications that re-
ported a high tendency for false positive detection of GDF pro-
teins in protein detection applications (Egerman et al., 2015), it
is important to note that the GDF3 protein induction during
CTX injury was undetectable in muscle samples from Gdf3/
animals (Figure 4H). To summarize, GDF3 is a macrophage-
derived protein whose expression is induced in various models
of muscle regeneration in a PPARg-dependent manner.
According to our model, the regeneration delay in macro-
phage PPARg-deficient animals was, at least partly, attributable
to a diminished macrophage-derived GDF3 secretion within
regenerating muscles. This model posits that GDF3 deficiency
inmacrophages should yield impairment in regeneration compa-
rable to what was observed in Ppargfl/fl Lyz2-cre animals.
Indeed, muscle regeneration after CTX injury was altered in
full-body Gdf3/ animals at day 8 (Figures 5A and 5B). It has
been reported that the full-body deletion of Gdf3 shows incom-
plete penetrance (Shen et al., 2009), which suggests possible
compensatory mechanisms. To limit their involvement and
ascertain the hematopoietic source of GDF3 during muscleImmunitregeneration, we generated BMT animals
reconstituted with Gfd3/ BM. When the
GDF3 chimeric animals were challenged
with CTX induced muscle injury, they
exhibited impairment in regeneration at
day 16 and 20 (Figures 5C and 5D).
When compared with WT BMT animals,
Gdf3/ chimeras contained more regen-
erating myofibers with smaller CSA andthe regenerating muscle was replete with lipid accumulations,
which are hallmarks of defective muscle regeneration (Figures
5C and 5D). Other cell types, such as fibro-adipogenic progeni-
tors (FAPs) are involved in muscle regeneration (Heredia et al.,
2013; Lemos et al., 2015). In line with our results from the
Gdf3/ BMT experiment (Figures 5C and 5D) and with the
mRNA and protein expression data showing GDF3 expression
in the CD45+ compartment (Figure 4), Pdgfra expressing FAP
cells isolated from D2 regenerating muscle barely expressed
Gdf3 and Lyz2 mRNA (Figure 5E), rendering the involvement of
FAPs unlikely in the macrophage-derived GDF3-driven effects
on muscle regeneration.
To further prove the requirement for GDF3 in muscle regener-
ation, we injected recombinant GDF3 into CTX injured muscles
of Ppargfl/fl Lyz2-cremice.We found that the exogenously added
GDF3 rescued the regeneration deficit seen in these animals
(Figures 6A and 6B). To characterize the function of GDF3 in
detail, we cultured primary myoblasts with or without recombi-
nant GDF3. We found GDF3 slightly decreased myoblast pro-
liferation (Figure 6C, left panel). We detected an even more
robust effect of GDF3 on myotube formation, as myoblasty 45, 1038–1051, November 15, 2016 1045
Figure 5. GDF3 Deficiency Impairs Muscle
Regeneration
(A and B) Myofiber CSA repartition (A) and mean
CSA (B) in CTX injured WT or Gdf3/ muscles at
day 8. Mean values ± SEM are shown. n = 7 for
both WT and Gdf3/ mice.
(C) Representative HE-stained muscle sections of
WT BMT and Gdf3/ BMT animals, 16 days post
CTX injury. Scale bars represent 50 mm. n = 4
muscles for both timepoints and genotypes.
(D) Myofiber CSA measurement in WT BMT and
Gdf3/KOBMTanimals, 16 and 20 days post CTX
injury. Mean values ± SEM are shown.
(E) Lack of Gdf3 and Lyz2 mRNA expression in
PDGFRA+ FAPs isolated from regenerating muscle
at day 2 post-injury. Mean values ±SEMare shown.
n = 3.cultures showed a pronounced increase in their fusion index
in the presence of GDF3 (Figures 6C, right panel, and 6D).
Myotube formation depends on cell motility, terminal differentia-
tion and cell fusion. In a specific fusion assay, we showed
that GDF3 was a potent inducer of myotube formation (Fig-
ure S7A), while a differentiation assay indicated that GDF3 did
not affect the terminal differentiation of myoblasts into myocytes
(Figure S7B).
Next, we investigated whether the SMAD2 phosphorylation
pathway, which is involved in the signal transduction of several
TGF-b superfamily members, is engaged during muscle regen-
eration. We found a detectable induction of in situ pSMAD2
signals in muscles at day 4 of regeneration (Figure 7A), at
the time when GDF3 expression peaked in the injured mus-
cle. Furthermore, SMAD2 phosphorylation was significantly1046 Immunity 45, 1038–1051, November 15, 2016increased during in vitro treatment of pri-
mary myoblasts with GDF3 (Figures 7B
and 7C).
In search for the molecular changes
triggered in muscle progenitors in the
presence of GDF3, we differentiated
in vitro primary myoblasts with or without
GDF3 and interrogated the gene-expres-
sion changes by RNA-seq. First, we
compared the profile of primarymyoblasts
andmyoblast-derivedmyotubes thatwere
cultured in the presence or absence of
GDF3. The expression pattern of a prese-
lected list of genes relevant to muscle
differentiation (Figure 7D) validated our
experimental system. Next, we compared
the expression profile of differentiating
myotubes cultured with or without GDF3.
The list of the differentially regulated
genes (Figure 7E and Table S2) showed
that a limited set of transcripts were either
induced or repressed in the presence of
GDF3. Several of the differentially regu-
lated genes, including Bex1, (Jiang et al.,
2016; Koo et al., 2007), Sgca (Matsumura
et al., 1992), andCamk1g, havebeen impli-cated in muscle regeneration, muscle structure and/or Ca2+ ho-
meostasis, showing that macrophage-derived GDF3 could elicit
biologically relevant changes during muscle regeneration.
If GDF3, a macrophage-derived secreted factor, can regulate
in vitro and in situ muscle differentiation and regeneration, then
wewanted to askwhether GDF3 is the onlymacrophage-derived
TGF-b family member that is relevant in the context of CTX
induced muscle injury. Therefore, we reanalyzed the transcrip-
tomic features of muscle infiltrative macrophages to chart the
expression and dynamics of the TGF-b family signaling system
(Figure 7F and Figure S7C). Three ligands (Gdf3, Gdf15, and
Inhba) showed notable gene expression dynamics in muscle
infiltrative macrophages. GDF3 expression peaked in repair
macrophages and showed definitive, consistent regulation by
PPARg. The two other family members (Figure S7C), Gdf15
Figure 6. Effects of Recombinant GDF3 on Muscle Differentiation
(A and B) Improvement in regeneration by administration of recombinant
GDF3 in Ppargfl/fl Lyz2-cre animals. (A) HE stained images and (B) CSA mea-
surements are shown.
(C) In vitro proliferation and differentiation assays on primary myoblasts in the
presence of recombinant GDF3. n = 4.
(D) IF against Desmin (red) and DAPI (blue) shows a drastic enhancement of
myotube formation in the presence of recombinant (r) GDF3 in the in vitro
primary myoblast myogenesis assay, n = 3. In all bar graphs, bars represent
mean ± SEM. For the effect of rGDF3 on myogenic differentiation and
fusion, see Figure S7. Scale bars represent 50 mm in each image in Figures
6A and 6D.and Inhba, were also regulated during muscle regeneration, and
both genes exhibited partial PPARg dependency. The PPARg-
GDF3 regulatory axis described in this study therefore identifies a
sensory-regulatory-effector mechanism, by whichmacrophages
are regulators of the tissue progenitor compartment, namely
MPCs. This axis orchestrates tissue regeneration, possibly in
unison with other members of the TGF-b family, leading to syn-
chronous regeneration.DISCUSSION
Skeletal muscle possesses excellent regenerative capacity,
therefore it was striking to see that after CTX injury, full-body
Ppargfl/ Sox2-cre animals showed signs of residual inflamma-
tion and impaired regeneration. The true extent of the involve-
ment of macrophage PPARg in the regeneration failure in these
animals is unclear for several reasons, including the uncharacter-
ized, but presumably inflammatory state of these animals and the
potential involvement of non-macrophage (e.g., muscle) PPARg
in regeneration. Therefore we used two distinct genetic models
(BMT and conditional PPARg deficiency, Ppargfl/fl Lyz2-cre),
which allowed us to focus on the role of PPARg in macrophages.
The delay in regeneration in macrophage PPARg-deficient ani-
mals was less profound than in the epiblastic Pparg/ mice,
yet it was detectable as long as three weeks after the initial injury,
thus appearing to be among the most dramatic reported defi-
ciencies in regeneration caused by impairments in macrophage
functions (Mounier et al., 2013).
Our analysis did not reveal a gross difference in macrophage
number or differentiation in Ppargfl/fl Lyz2-cre animals, unlike
two other reported experimental systems where AMPK or IGF1
deficiency in muscle infiltrative macrophages led to altered
macrophage differentiation (Mounier et al., 2013; Tonkin et al.,
2015). Although alternatively activated macrophages have
been implicated in tissue repair and PPARg has been reported
to be a regulator of alternative macrophage polarization (Ode-
gaard et al., 2007), we have previously reported that muscle
Ly6C+ and Ly6Cmacrophages do not correspond to canonical
alternatively polarized macrophage populations (Varga et al.,
2016) in the CTX model. Therefore, it is not surprising that, in
this model, PPARg is controlling genes other than alternative
macrophage- related ones, reported to be PPARg-dependent
in other tissue compartments and contexts (Odegaard et al.,
2007). The fact that the regeneration impairment in Stat6/
animals did not manifest in a decrease in CSA, also suggest
that PPARg, in this experimental context, acts through mecha-
nisms other than modulating alternative macrophage activation.
Systematic transcriptomic analyses, however, provided clues
about both the sensory and the regulatory roles of PPARg in
muscle-infiltrating macrophages. It is important to stress that
earlier descriptions of direct PPARg transcriptional target genes
often reported lipid metabolic genes as the main targets of
PPARg in macrophages, which could poorly explain the anti-in-
flammatory role of the receptor (Szanto et al., 2010; Welch et al.,
2003). We report here that the transcriptional activity of PPARg
is unique in muscle macrophages, because the most robustly
changing genes (such as Saa3, Hebp1) were linked to inflam-
mation, rather than to lipid metabolism. Second, in vivo treat-
ment with RSG identified the Ly6C repair macrophages as an
in situ macrophage subtype that could be activated by a syn-
thetic ligand for PPARg. The surprising fact that RSG treatment
elicited characteristically different gene-expression changes in
Ly6C+ and Ly6C macrophages isolated from the same tissue
and timepoint underscores the notion that distinct macrophage
subsets have differential responses to environmental cues. A
possible interpretation of the available datawould be the involve-
ment of a yet unidentified endogenous ligand for PPARg whose
activity is restricted to the Ly6C compartment, which couldImmunity 45, 1038–1051, November 15, 2016 1047
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Figure 7. Effects of GDF3 on Myogenesis
(A) Increased pSmad2 phosphorylation in regenerating muscles peaking at day 4 post CTX injury.
(B and C) Increased Smad2 phosphorylation in primary myoblasts treated with rGDF3. IF images and percentage of pSMAD2-positive cells are shown. Mean
values ± SEM are shown. n = 3.
(D) Heatmap representation of the expression changes of myogenic genes validating the utilized in vitro primary myoblast assay.
(E) Heatmap representation of genes that are differentially expressed (min. fold change difference of 1.2X between differentiated myoblasts ± rGDF3) in the
presence of recombinant GDF3 during myoblast differentiation.
(F) Heatmap representation of members of the TGF-b superfamily signaling system that are expressed and regulated, or expressed but not regulated in muscle
derived macrophages. For non-expressed members, see Figure S7C.
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explain the tendency of otherwise RSG inducible genes to be
upregulated in the Ly6C macrophages even in the absence of
the synthetic ligand. Whether the dynamic regulation of in situ
eicosanoid synthesis we detected during regeneration could
be behind the apparent ligand activation of the receptor requires
further investigation.
From the perspective of muscle regeneration, the most
notable finding was the identification of GDF3, a TGF-b family
member, which showed consistent regulation by PPARg in all
relevant macrophage subtypes. To ascertain that GDF3 was
not only a PPARg-dependent factor, but also a direct PPARg
target, we analyzed an extensive range of genomic and epige-
nomic data. Although it is clear that GDF3 is expressed in a
PPARg-dependent fashion and can be induced by ligand inmus-
cle-derived Ly6C macrophages, direct regulation by PPARg is
challenging to prove, because ligand-dependent regulation ap-
pears to be macrophage subtype specific and not detectable
in BMDMs. However, we have provided data that are consistent
with direct regulation, even in BMDMs.
It is noteworthy that both GDF3 gene and protein expressions
were much lower in the CD45 fraction isolated from injured
muscle than in the hematopoietic compartment. Considering
that the separation of CD45+ cells is inherently incomplete,
our results indicate that macrophages are the predominant, if
not the only, source of GDF3 within the injured tissue. This exclu-
sivity sets GDF3 apart from other macrophage-derived regen-
erative factors, such as IGF1 (Tonkin et al., 2015), which is also
produced by muscle and in the liver upon injury. The timing
and localization of GDF3 protein in the CTX and other, unrelated
injury models firmly suggested that GDF3 is a general, macro-
phage-specific regulator of muscle regeneration.
To link macrophage biology to tissue regeneration, we
analyzed the role of macrophage derived GDF3 in muscle
regeneration in a combination of in vivo and in vitro approaches.
Foremost, two genetic models of GDF3 deficiency reported a
delay in regeneration. While the decrease in average CSA in
Gdf3/ animals was comparable to that seen in Ppargfl/fl
Lyz2-cre animals, Gdf3/ animals did not display persistent
inflammation and delayed resolution of necrotic and/or phago-
cytic fibers. This suggested that PPARg regulated several rele-
vant pathways during regeneration. Notably, a gain of function
experiment revealed that exogenous GDF3 could counteract
the deleterious effect PPARg deficiency in macrophages. Our
in vitro results with BMDM supernatants and myoblasts indi-
cated the presence of a regulatory circuit betweenmacrophages
and muscle cells and showed that GDF3 appeared to be an
especially robust enhancer of myoblast fusion.
Because other cell types are also involved in the regeneration
process (Heredia et al., 2013; Joe et al., 2010; Uezumi et al.,
2010), it cannot be excluded that GDF3 is only one of the
TGF-b family members that are active during regeneration and
that it has effects on other cell types such as FAPs as well. It is
remarkable, though, that the key elements of themyogenic cross
talk between cell types can be modeled in vitro using macro-
phages and myoblasts only, arguing that these two cell types
and their interactions are critical to support regeneration.
Our findings also carry potential implications for pathological
circumstances in which recurrent muscle damage and asyn-
chrony in repair due to genetic conditions leads to debilitatingdegenerative muscle diseases, such as Duchenne Muscular
Dystrophy (DMD). It is of great importance to determine whether
GDF3 is also a regulator of muscle regeneration in DMD or
other types of myopathies, which are most of the time associ-
ated with the permanent presence of inflammatory cells, espe-
cially macrophages.
EXPERIMENTAL PROCEDURES
For more detailed descriptions of experimental procedures, please see
Supplemental Experimental Procedures.
Mice
Ppargfl/flLyz2-cre+ and wild-type C57BL/6J controls, Ppargfl/Sox2-cre+ and
littermate control Ppargfl/+Lyz2-cre animals, and Gdf3/ and littermate
C57BL/6 albino controls were used in the experiments. All experimental
procedures conducted on animals were carried out in accordance with institu-
tional regulations.
Muscle Injury
Mice were anaesthetized with isoflurane and 50 ml of cardiotoxin (12 3 106
mol/l in PBS) was injected in the TA muscle. Muscles were recovered for
flow cytometry analysis at day 1, 2, or 4 post-injury or for muscle histology
at day 8 post-injury.
Histological Analysis of Muscle Regeneration
Muscles were removed and snap frozen in nitrogen-chilled isopentane
(–160C). 8 mm thick cryosections were cut and stainedwith hematoxylin-eosin
(HE). HE stained sections were analyzed for cross sectional area (CSA) or for
the presence of phagocytic fibers. Day 8 post CTX slides were also IF stained
for Desmin / F4/80 / DAPI.
Macrophage Cell Culture for Conditioned Medium Generation
Macrophages were obtained from bonemarrow (BM) precursor cells that were
cultured in DMEMmediumcontaining 20%FBS and 30%conditionedmedium
of L929 cell line (enriched in CSF-1) for 7 days. Macrophages were activated
with IFN-g (50 ng/ml) or IL-4 (10 ng/ml) to obtain macrophage-conditioned
medium.
Myogenic Precursor Cell Culture
MurineMPCswere obtained from TAmuscle and cultured using standard con-
ditions in DMEM/F12 (Gibco Life Technologies) containing 20% FBS and 2%
Ultroser G (Pall, Inc). For proliferation studies, MPCs were incubated for 1 day
with conditioned medium + 2.5% FBS or with 2.5% FBS medium containing
GDF3 mouse recombinant protein. Cells were then incubated with anti-ki67
antibodies (15580 Abcam), which were subsequently visualized using cy3-
conjugated secondary antibodies (Jackson Immunoresearch, Inc). For differ-
entiation studies, MPCs were incubated for 3 days with conditioned medium
containing 2% horse serum or with 2% horse serum medium containing
GDF3. Cells were then incubated with anti-desmin antibodies (32362 Abcam),
in combination with a cy3-conjugated secondary antibody (Jackson Immunor-
esearch Inc).
Phagocytosis Assay
BMDM cells and C2C12 cells were stained with CellVue or PKH67 (Sigma),
respectively. Heat-killed stained C2C12 were used as phagocytic sub-
strates for stained BMDMs and fluorescent intensity was measured with a
FACScalibur instrument.
Image Capture and Analysis for Myoblast Cultures
Fusion index (for myogenic cells) was calculated as the number of nuclei within
myotubes divided by the total number of nuclei, nuclei number being esti-
mated using the ImageJ software.
Isolation of Macrophages from Muscle
CD45+ cells were isolated from CTX injected muscles using magnetic sorting
(Miltenyi Biotec). CD45+ cells then were labeled with fluorescently labeledImmunity 45, 1038–1051, November 15, 2016 1049
antibodies and Ly6C+ F4/80low macrophages, Ly6C F4/80+ macro-
phages, and Ly6Cmid F4/80 neutrophils were analyzed and sorted with a
BD FACSAria III sorter.
RNA Isolation from Sorted MFs
Macrophage subsets were sorted from day 1, 2, and 4 post-injury muscles
with a FACSAria III sorter and total RNA was isolated with TRIZOL reagent
according to the manufacturer’s recommendation.
Microarray Analysis of Muscle Macrophages
Global expression pattern was analyzed on Affymetrix GeneChip Mouse Gene
1.0 ST arrays. The microarray data are publicly available (GEO: GSE71155).
Chromatin Immunoprecipitation
ChIP was carried out in BMDMs using antibodies against pre-immune immu-
noglobulin G (IgG) (Millipore, 12-370), (pan) RXR (sc-774 Santa Cruz Biotech-
nology), and PPARg (Perseus #PP-A3409A).
Bioinformatic Analysis of the Active Enhancers around theGdf3 and
Angptl4 Locus
The list of published and/or publicly available datasets used for visualization in
IGV2 to identify active enhancers can be found in the Supplemental Experi-
mental Procedures section.
Western Blotting
GDF3 protein expression was measured using western blot analysis. Samples
from CTX injected TA muscles or CD45+ cells were lysed in RIPA buffer. GDF3
was targeted using rabbit monoclonal Anti-GDF3 primary antibody (ab109617,
Abcam) at 1:1,000 dilution in TBS-T supplemented with 5% BSA overnight at
4C. Anti-GAPDH mouse monoclonal primary antibody (AM4300, Ambion)
was used as a protein loading control at 1:10,000–1:20,000 dilution in TBS-T
supplemented with 5% BSA overnight at 4C.
RNA Sequencing Library Preparation for Myoblast Gene-Expression
Analysis
cDNA library for RNA-seq was generated from 1 mg total RNA using TruSeq
RNA Sample Preparation Kit (Illumina) according to the manufacturer’s proto-
col. The RNA-Seq data are publicly accessible (SRA: PRJNA290560).
General Statistical Analyses
All experiments were performed using at least three different samples. Stu-
dent’s t-tests and two-way ANOVA analyses were performed and p < 0.05
was considered significant (*p % 0.05, **p % 0.01, ***p % 0.001). Mean and
SD values, or mean and SEM values are shown in graphs.
ACCESSION NUMBERS
The microarray data are publicly available in the GEO database under acces-
sion number GSE71155 and the RNA-Seq data are publicly accessible under
SRA: PRJNA290560.
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mental Experimental Procedures and can be found with this article online at
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